Johnson & Johnson and the United States Department of Health pushed 1 billion dollars into a possible vaccine against coronavirus Covid-19 being developed by Janssen Vaccines & Prevention in Leiden, a subsidiary of the American company. Johnson & Johnson hopes to have the first batches of Covid-19 vaccines ready for emergency authorization by early next year, the company said in a statement.
American medical group Johnson & Johnson is working with over 100 people in Leiden on a vaccine against coronavirus Covid-19, but this vaccine will likely not be tested in the Netherlands. The rules for clinical tests on humans are stricter in the Netherlands than in other countries, and the group wants to avoid delays, Financieele Dagblad reports.
Some 43 coronavirus patients died in the Netherlands since Saturday, with the nation now mourning the loss of 179 people, public health agency RIVM said on Sunday. The agency also announced that another 573 tested positive for the virus, pushing the total number of diagnosed patients to 4,204, nearly four-times the number of patients recorded on March 15.
Just one week ago, the total number of patients in the Netherlands was 1,077. By that date, a total of 20 people who tested positive for the virus had died, a figure which has increased by 800 percent in the past seven days.
A team of ten scientific researchers from the Erasmus Medical Center in Rotterdam and Utrecht University say they are the first in the world to discover an antibody capable of fending off an infection by the Covid-19 variant of coronavirus. The discovery could lead to an antiviral medication, and the ability for people to test themselves at home for the presence of the virus.
Wageningen University received a subsidy of 12.5 million euros to create a vaccine against the mosquito borne virus Rift Valley Fever that is safe for humans. The subsidy comes from the Coalition for Epidemic Preparedness Innovation (CEPI), NOS reports.
After ten years of research and testing by the university hospitals in Leiden and Nijmegen, a malaria vaccine seems to be on the horizon. Tests on 19 human subjects in the Netherlands over the past six months seem to indicate a breakthrough. They were injected with genetically weakened malaria parasites and none of them got malaria, NOS reports.
The Radboud University Medical Center in Nijmegen is teaming up with Erasmus MC and the Haven hospital in Rotterdam for an experiment in using a parasite found in mice for a new malaria vaccine for humans. The first three volunteers were given a genetically modified rodent malaria as vaccine on Tuesday, the Telegraaf reports.
Professor Bart Haagmans and his team of scientists at the Erasmus Medical Center believe that they are one step closer to developing a vaccine that protects against the MERS virus. Their vaccine managed to protect camels from developing symptoms of the virus
After 17 years of research and hard work, researchers from the Amsterdam Academic Medical Center and the Cornell University in New York have take a major step in the process of developing a vaccine against the AIDS virus. They have managed to create a vaccine that work against two variants of the AIDS virus in animals.
Dutch drug manufacturer Janssen Pharmaceutical Companies started testing an Ebola vaccine on humans this week. The Johnson & Johnson subsidiary produced 400,000 doses of the vaccine for large-scale clinical trials that could launch by April, the firm said in a statement.
In Overijssel, two Municipal Healtcare Service's (GGD) in the region of Twente have reported a rise in cases of whooping cough. Nurses are warning those vaccinated that their cough might not be a nasty cold after all, RTV Oost reports.
A bio-tech company in Leiden is making headway developing a vaccine against the deadly, and fast-spreading ebola virus. In an interview with Het Financieele Dagblad, Maria Pau, head of the research program, says that data from tests on monkeys is very promising.
A new study conducted under leadership from UMC Utrecht has discovered that the chance for the elderly to develop lung infections can be greatly reduced by a vaccine.